NanoViricides, Inc. Reports That Oral Administration of FluCide®, Its Anti-Influenza Drug Candidate Was Effective in Animal Model
Published: Aug 13, 2012
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that an anti-influenza drug candidate under its FluCide™ program is effective when given orally. The Company has received information that a FluCide drug candidate designed for oral administration has shown very strong efficacy in corresponding animal studies. This information was received from the contract laboratory that performed the studies, namely, KARD Scientific, Inc. The studies involved the same highly lethal animal model the Company has continued to use for its influenza drug development program. The Company is awaiting data from the studies and intends to release additional information as the data are analyzed and studied.